Grifols, S.A. (BME:GRF) acquired 32.9% in Progenika Biopharma, S.A. from Minerales y Productos Derivados, S.A. (BDM:MYD) for €25 million in cash and stock on March 3, 2016. 50% of the purchase price has been paid in exchange for 876,777 non-voting class B shares of Grifol and rest in cash. Grifols acquired 0.01 million shares in Progenika. Osborne Clarke acted as legal advisor for Grifols. Cuatrecasas Gonçalves Pereira acted as legal advisor for Minerales y Productos.

Grifols, S.A. (BME:GRF) completed the acquisition of an unknown stake in Progenika Biopharma, S.A. from Minerales y Productos Derivados, S.A. (BDM:MYD) on March 3, 2016.